Related Experiment Video
Updated: Nov 1, 2025
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Clinical failure of natalizumab in multiple sclerosis: Specific causes and strategy
D Guery1, R Marignier2, F Durand-Dubief3
1Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, hôpital Neurologique Pierre Wertheimer, hospices civils de Lyon, 69677 Lyon/Bron, France.
Background:
Natalizumab is a very effective treatment of multiple sclerosis (MS). Failure is rare and should lead to consider some specific etiologies. The purpose of our study was to describe causes of subacute neurological events under natalizumab.
Methods:
Observational single-center retrospective study in the MS expert center of Lyon, France.
Inclusion Criteria:
any patient with definite MS who received at least three infusions of natalizumab between April 2007 and February 2017. Clinical data were extracted from the Lyon EDMUS/OFSEP database. Events of interest: occurrence of a subacute neurological deficit, characterized by new clinical symptoms. We excluded pseudo-relapses and progression.
Findings:
A subacute neurological deficit occurred in 35 cases, for 607 patients treated with natalizumab. Ten patients presented natalizumab antibodies, nine had progressive multifocal leukoencephalopathy (PML), five presented an isolated subacute neurological deficit and two had AQP4 antibodies. No myelin oligodendrocyte glycoprotein (MOG) antibodies were found.
Interpretation:
The occurrence of an acute or subacute neurological deficit with natalizumab is rarely a MS relapse and should lead systematically to explore some important alternate etiologies, eliminating PML first.
